| Article ID | Journal | Published Year | Pages | File Type |
|---|---|---|---|---|
| 5659649 | Gastrointestinal Endoscopy | 2017 | 35 Pages |
Abstract
SOCÂ + PTX is safe but does not improve overall survival or overall tumor response at the primary tumor site for patients with local or locoregional cancer of the esophagus/gastroesophageal junction. (Clinical trial registration number: NCT00573131.)
Keywords
modified intention to treatNCI CTCAE5-FUSCCCrtmRECISTECoGPTXKPSSAEDLTmITTTEAEstandard of caredose-limiting toxicityRadiotherapySOCeastern cooperative oncology groupChemoradiotherapyadverse eventSerious adverse eventTreatment-emergent adverse eventsconfidence interval5-fluorouracilNational Cancer Institute Common Terminology Criteria for Adverse EventsPCRKarnofsky performance statuscomplete responsepathologic complete responsePaclitaxelSquamous cell carcinoma
Related Topics
Health Sciences
Medicine and Dentistry
Gastroenterology
Authors
John M. MD, FACG, FASGE, AGAF, S. Krishna MD, Ramesh MS, MCh(GE), FRCS(G), G. Aaron MD, Grzegorz MD, Paul MD, Claire MS, Kirk PhD,